MRFR Year End Sale
Central Pontine Myelinolysis Market Research Report- Global Forecast till 2030

Central Pontine Myelinolysis Market Information: By Diagnosis (Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), Electroencephalography, Others) By Treatment (Vitamin Supplementation, Electrolyte Mainainence, others)) By End Users - Global Forecast till 2030

ID: MRFR/Pharma/3161-HCR | December 2022 | Region: Global | 80 Pages         

Central Pontine Myelinolysis Market Speak to Analyst Request a Free Sample

Market Synopsis of Global Central Pontine Myelinolysis Market


Market scenario

The Central Pontine Myelinolysis Market is expected to reach USD 5,212.7 Million by 2030 at 7.9% CAGR during the forecast period 2022-2030. Central Pontine Myelinolysis (CPM), also known as osmotic demyelination syndrome or central pontine demyelination, is a neurological disorder caused by severe damage of the myelin sheath of neurons. CPM mostly affects the pons area of the brain and is characterized by acute paralysis, difficulty swallowing (dysphagia), difficulty speaking (dysarthria), and other neurological symptoms. These neurological symptoms are manifested into nausea and vomiting, disturbed consciousness, gait changes, confusion, headache, seizures etc. Serious progressive neurological symptoms are the progressive development of spastic tetraparesis, pseudobulbar palsy etc.

The causes of CPM are, rapid correction of low blood sodium levels (hyponatremia) affected by severe liver disease, liver transplant, alcoholism, severe burns, malnutrition, anorexia, severe electrolyte disorders, AIDS, hyperemesis gravidarum, anorexia nervosa, hematopoietic stem cell transplantation, Wernicke encephalopathy etc. The market drivers for central pontine myelinolysis market are increase in the risk factors such as hyponatremia cases, increasing screening and penetration of healthcare, growing income and healthcare expenditure etc. The market restraints are poor cure rates of central pontine myelinolysis, treatment, high cost of treatment etc.

Research Methodology: Central Pontine Myelinolysis Market

Sources: Mayo Clinic, Healthline Media, U.S. Department of Health and Human Services MRFR Analysis


Intended Audience



  • Global central pontine myelinolysis treatment manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1           Global Central Pontine Myelinolysis Market by Diagnosis, 2016 (% market share) Global Central Pontine Myelinolysis Market

Segments:


The global central pontine myelinolysis market has been segmented on the basis of diagnosis, treatment, and end users.


Based on diagnosis, the market has been segmented as magnetic resonance imaging (MRI), computerized tomography (CT), electroencephalography and others.


Based on treatment, the market has been segmented as vitamin supplementation, electrolyte mainainence and others.


Based on the end users, the market has been segmented as hospitals & clinics, academic and research and others.


Regional analysis:


The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care driven by the increasing incidence of related diseases and clinical conditions that can cause CPM. Additionally, the fastest uptake of new drugs in the US drives the central pontine myelinolysis market. Also, concentration of major research companies and hospitals in the developed countries of this region is adding fuel to the market growth. The large expenditure on the US healthcare, accounting to 16% of GDP, also cruises the sale of central pontine myelinolysis treatment.


Europe is the second largest market in the world due to high income and healthcare penetration. Europe is led by nations such as Germany and France. UK is expected to be the fastest growing market.


Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.


Key Players in the Global Central Pontine Myelinolysis Market


Some of key players profiled in the report are Fujifilm Holdings Corporation, GE Healthcare, Siemens Healthcare GmbH, Philips Healthcare (Koninklijke Philips N.V.), Shimadzu Corporation, Toshiba Medical Systems Corporation, Carestream Health, Hitachi Medical Corporation and others.


The report for Global Central Pontine Myelinolysis market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 5,212.7 Million
  CAGR   7.9%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Fujifilm Holdings Corporation, GE Healthcare, Siemens Healthcare GmbH, Philips Healthcare (Koninklijke Philips N.V.), Shimadzu Corporation, Toshiba Medical Systems Corporation, Carestream Health, Hitachi Medical Corporation
  Key Market Opportunities

  • The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care
  • Europe is the second largest market in the world due to high income and healthcare penetration
  • Asia Pacific region is expected to grow rapidly and China and India are likely to lead this market due to fast growing healthcare sector during the forecast period.\r\nThe African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development
  •   Key Market Drivers

  • Increasing screening and penetration of healthcare
  • Growing income and healthcare expenditure


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    central pontine myelinolysis market is projected to grow at approximately 7.9% CAGR during the assessment period (2022-2030).

    central pontine myelinolysis market is estimated to reach a valuation of approx. USD 5,212.7 Million by the end of 2030.

    increase in the risk factors such as hyponatremia cases and the rising per capita healthcare expenditure, are major tailwinds pushing the growth of the global central pontine myelinolysis market.

    North America holds the largest share in the global central pontine myelinolysis market, followed by Europe and the Asia Pacific, respectively.

    Fujifilm Holdings Corporation, Philips Healthcare (Koninklijke Philips N.V.), GE Healthcare, Siemens Healthcare GmbH, Toshiba Medical Systems Corporation, Shimadzu Corporation, Carestream Health, and Hitachi Medical Corporation, are some of the top players operating in the global central pontine myelinolysis market.